Cyllene Therapeutics

Cyllene Therapeutics is developing next-generation precision genetic medicines for prevalent chronic diseases using its proprietary non-replicative Herpes Simplex Virus 1 (nrHSV-1) HERMES platform, which enables safe, targeted, and durable transgene expression in peripheral neurons. The company's initial focus is on underserved bladder and neuro-urology disorders with high unmet medical need, with its lead programme EG110A currently in clinical development as the first non-replicative herpes vector-based genetic medicine evaluated in humans.

Cyllene Therapeutics is headquartered in Paris, France, and is backed by an experienced investor syndicate including Andera Partners, Bpifrance, SCI, GordonMD, among others.